Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2001;37:e12

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Balas, E. A.
Right arrow Articles by Knapp, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balas, E. A.
Right arrow Articles by Knapp, D. A.

(Hypertension. 2001;37:e12.)
© 2001 American Heart Association, Inc.


Letters to the Editor

Trends in Antihypertensive Drug Therapy by US Office-Based Physicians

E. Andrew Balas

Center for Health Care Quality, University of Missouri-Columbia, Columbia, Missouri


*    Introduction
up arrowTop
*Introduction
down arrowReferences
down arrowIntroduction 
 
To the Editor:

We read with great interest the article by Nelson and Knapp1 on the trends of antihypertensive therapy by US office-based physicians. Their findings are clearly significant, but some of their conclusions are not supported by the data presented. The authors state that "physician antihypertensive drug prescribing was generally consistent with the basic antihypertensive drug guidelines of the JNC reports." However, they also note that calcium channel blocker visits increased from 1.9% in 1985 to 39.8% in 1995 and that ACE inhibitor/receptor blocker visits increased from 6.4% to 37.0%, while all other drug classes decreased, including the JNC’s preferred step 1 agents of ß-adrenergic blockers and diuretics. Moreover, while in 1995 monotherapy with either calcium channel blockers or ACE inhibitors together made up 39.5%, monotherapy with the JNC V’s preferred step 1 monotherapy of either diuretics or ß-adrenergic blockers accounted for only 19.6% of antihypertensive drug visits.1 This is much more in accordance with the findings of previous studies in the United States2 and Europe,3 4 which found no effect of prescription guidelines on antihypertensive therapy by physicians. The profound increase in newer, expansive, patented products such as calcium channel blockers, ACE inhibitors, and angiotensin receptor blockers seen in this and other studies has been attributed to the effect of intense promotion by drug manufacturers.3 5 One can only wonder why doctors do not follow recommendations by their professional organizations but rather the promotion campaigns of pharmaceutical companies, and what could be done to change this unfavorable situation.


*    References
up arrowTop
up arrowIntroduction
*References
down arrowIntroduction 
 
1. Nelson CR, Knapp DA. Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians. Hypertension. 2000;36:600–603.[Abstract/Free Full Text]

2. Siegel D, Lopez J. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 997;278:1745–1748.

3. Szekacs B, Vajo Z, Szepezdi Z. Diuretics for hypertension JAMA.. 1999;282:524.

4. Jabary NS, Herrero AM, Gonzalez JA. The use of antihypertensive therapy in Spain (1986–1994). Am J Hypertens. 2000;13:607–610.[Medline] [Order article via Infotrieve]

5. Moser M. Why are physicians not prescribing diuretics more frequently in the management of hypertension? JAMA. 1998;279:1813–1816.[Abstract/Free Full Text]

Response

Cheryl R. Nelson

Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland

Dee A. Knapp

Department of Pharmacy Practice and Science, School of Pharmacy, University of Maryland\.


*    Introduction 
up arrowTop
up arrowIntroduction
up arrowReferences
*Introduction 
 
Clearly, what is needed to address your concerns is a better explanation of what we meant by "basic antihypertensive drug guidelines of the JNC reports." What we meant as "basic" is any of the "initial" step 1 antihypertensive drug classes as given in JNC V (Table 7) and JNC VI (Figure 8) (see our article for references).





This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Balas, E. A.
Right arrow Articles by Knapp, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balas, E. A.
Right arrow Articles by Knapp, D. A.